Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
The Zacks Analyst Blog Highlights Marathon Petroleum, Ulta Beauty, HF Sinclair, ShockWave Medical and Paylocity
by Zacks Equity Research
Marathon Petroleum, Ulta Beauty, HF Sinclair, ShockWave Medical and Paylocity are part of The Zacks top Analyst Blog.
Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both of its segments.
Zacks Industry Outlook Highlights ShockWave Medical, Semler Scientific and Asensus Surgical
by Zacks Equity Research
ShockWave Medical, Semler Scientific and Asensus Surgical are part of Zacks Industry Outlook article.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Top 5 Momentum Stocks to Brace for a Scary September
by Nalak Das
We have narrowed our search to five large-cap momentum stocks that have solid upside left for September. These are: SWAV, PCTY, DINO, MPC and ULTA.
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on R&D investments. SWAV, SMLR and ASXC are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is disrupting the trend.
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.
Veeva Systems (VEEV) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) Q2 earnings are likely to have been driven by strength in its commercial business.
Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Here's Why You Should Buy ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
LHC Group (LHCG) to Expand Access in Georgia With New Buyout
by Zacks Equity Research
LHC Group (LHCG) is set to acquire Georgia-based Three Rivers Home Health that will expand its service footprint in 36 counties in the state of Georgia.
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
by Zacks Equity Research
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
Here's Why Shockwave Medical (SWAV) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Shockwave Medical (SWAV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Buy Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Can Shockwave Medical (SWAV) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Shockwave Medical (SWAV) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.
Catalent (CTLT) to Acquire New CDMO Facility for $475 Million
by Zacks Equity Research
Catalent (CTLT) agrees to buy Mayne Pharma's specialty CDMO division, Metrics Contract Services, for $475 million. The deal is expected to be completed by 2022-end.
CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez
by Zacks Equity Research
CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.
Shockwave Medical (SWAV) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and expansion in gross margin.
DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.
Shockwave Medical (SWAV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 58.14% and 12.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Shockwave Medical (SWAV) have performed compared to their sector so far this year.